Let’s start up with the current stock price of Lineage Cell Therapeutics Inc. (LCTX), which is $2.28 to be very precise. The Stock rose vividly during the last session to $2.50 after opening rate of $2.43 while the lowest price it went was recorded $2.27 before closing at $2.44.
Recently in News on April 12, 2021, OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD. Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021), to be held virtually (May 1 – 7, 2021). The presentation, “Phase I/IIa Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD): Interim Results” will be featured as part of the Stem cells/Gene Therapy/Transplantation Session, on May 6, 2021 between 5:15 pm and 6:45 pm EDT by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine. (abstract number 3538173). You can read further details here
Lineage Cell Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.13 on 02/17/21, with the lowest value was $1.55 for the same time period, recorded on 03/05/21.
Lineage Cell Therapeutics Inc. (LCTX) full year performance was 181.48%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Lineage Cell Therapeutics Inc. shares are logging -27.19% during the 52-week period from high price, and 225.71% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.70 and $3.13.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1223299 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Lineage Cell Therapeutics Inc. (LCTX) recorded performance in the market was 29.55%, having the revenues showcasing 9.62% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 361.36M, as it employees total of 49 workers.
Analysts verdict on Lineage Cell Therapeutics Inc. (LCTX)
During the last month, 0 analysts gave the Lineage Cell Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.17, with a change in the price was noted +0.88. In a similar fashion, Lineage Cell Therapeutics Inc. posted a movement of +62.86% for the period of last 100 days, recording 1,626,407 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for LCTX is recording 0.01 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Lineage Cell Therapeutics Inc. (LCTX): Technical Analysis
Raw Stochastic average of Lineage Cell Therapeutics Inc. in the period of last 50 days is set at 46.16%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 32.73%. In the last 20 days, the company’s Stochastic %K was 50.31% and its Stochastic %D was recorded 65.52%.
Let’s take a glance in the erstwhile performances of Lineage Cell Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 29.55%. Additionally, trading for the stock in the period of the last six months notably improved by 115.09%, alongside a boost of 181.48% for the period of the last 12 months. The shares increased approximately by -6.17% in the 7-day charts and went up by -6.17% in the period of the last 30 days. Common stock shares were driven by 9.62% during last recorded quarter.